This Article Full Text Full Text (PDF) All Versions of this Article: 38/8/2279    most recent STROKEAHA.107.487009v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Saver, J. L. Search for Related Content PubMed PubMed Citation Articles by Saver, J. L. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Stroke Related Collections Health policy and outcome research Thrombolysis Acute Cerebral Hemorrhage Acute Cerebral Infarction Acute Stroke Syndromes Emergency treatment of Stroke Fibrinolysis Related Article

(Stroke. 2007;38:2279.)
© 2007 American Heart Association, Inc.

Original Contributions

Hemorrhage After Thrombolytic Therapy for Stroke

The Clinically Relevant Number Needed to Harm

Jeffrey L. Saver, MD

From the Stroke Center and the Department of Neurology, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, Calif.

Correspondence to Jeffrey L. Saver, MD, UCLA Stroke Center, 710 Westwood Plaza, Los Angeles, CA 90095. E-mail jsaver{at}ucla.edu

Background and Purpose— A clinically relevant number needed to harm for tissue plasminogen activator (tPA)-related symptomatic intracerebral hemorrhage (SICH) would greatly assist therapeutic decision-making.

Methods— A 15-variable prognostic model was derived from a placebo group enrolled in National Institute of Neurological Disorders and Stroke tPA Trials 1 and 2 and used to predict final global disability outcome for patients with tPA-related SICH had they been treated with placebo, rather than tPA, and not experienced SICH.

Results— Among 312 tPA-treated patients, 20 experienced SICH. Compared with placebo patients, patients treated with tPA who experienced SICH were older, had more severe stroke deficits, had higher serum glucose levels, and more often displayed mass effect on pretreatment imaging. Observed 3-month modified Rankin Scale outcomes among the patients experiencing SICH after tPA were: 0–5%, 1–5%, 4–10%, 5–5%, and 6–75%. Predicted outcomes had they been treated with placebo were: 0–2%, 1–5%, 2–7%, 3–14%, 4–28%, 5–12%, and 6–32%. The number needed to harm for one more patient to have a final disabled or dead outcome (modified Rankin Scale 3) attributable to tPA-related SICH was 707. Number needed to harm for severely disabled or dead outcome (modified Rankin Scale 4) was 126; for fatal outcome 36.5, and for worsened outcome by any degree (1 modified Rankin Scale grade) between 29.7 and 40.1.

Conclusions— Most patients who experience SICH have severe baseline infarcts and already are destined for poor outcomes. For every 100 patients treated with tPA, approximately 1 will experience a severely disabled or fatal final outcome as a result of tPA-related SICH.

Key Words: intracerebral hemorrhage • ischemic stroke • number needed to treat • stroke • thrombolysis

Related Article:

Thrombolytic Therapy for Acute Ischemic Stroke: The Likelihood of Being Helped Versus Harmed

Bart M. Demaerschalk
Stroke 2007 38: 2215-2216. [Full Text] [PDF]

This article has been cited by other articles:

				M. Paciaroni, G. Agnelli, F. Corea, W. Ageno, A. Alberti, A. Lanari, V. Caso, S. Micheli, L. Bertolani, M. Venti, et al. Early Hemorrhagic Transformation of Brain Infarction: Rate, Predictive Factors, and Influence on Clinical Outcome: Results of a Prospective Multicenter Study Stroke, August 1, 2008; 39(8): 2249 - 2256. [Abstract] [Full Text] [PDF]